Skip to main content
SpringerLink
Log in

Treatment Sequencing for Borderline Resectable Pancreatic Cancer

  • Chapter
  • First Online:
Management of Localized Pancreatic Cancer

  • 441 Accesses

Abstract

Borderline resectable pancreatic cancer accounts for approximately 7-10% of all patients diagnoses with pancreatic cancer each year. Because there is significant tumor-vascular interface, patients are at a high risk of margin-positive resection with a surgery first approach. We advocate for a multimodal approach to the management of these patients in order to mitigate this risk. In this chapter we will discuss the rational for use of preoperative systemic therapy and local-regional chemoradiation in borderline resectable pancreatic cancer to improve R0 resection rates and provide the best chance for favorable long-term outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. NooneAM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA,editors. SEER cancer statistics review, 1975–2015. Bethesda: National Cancer Institute; 2018.https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER website, April 2018. Accessed 2 May 2018.

  2. Hammel P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–53.

    Article  CAS  PubMed  Google Scholar 

  3. Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  4. Von Hoff DD, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  Google Scholar 

  5. Varadhachary GR, et al. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol. 2005;8(5):377–84.

    Article  PubMed  Google Scholar 

  6. Katz MH, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46; discussion 846–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ferrone CR, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.

    Article  PubMed  Google Scholar 

  8. Brennan DD, et al. Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics. 2007;27(6):1653–66.

    Article  PubMed  Google Scholar 

  9. Balachandran A, et al. Imaging of pancreatic neoplasms. Surg Oncol Clin N Am. 2014;23(4):751–88.

    Article  PubMed  Google Scholar 

  10. Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20(24):7864–77.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lee JK, et al. Prediction of vascular involvement and resectability by multidetector-row CT versus MR imaging with MR angiography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma. Eur J Radiol. 2010;73(2):310–6.

    Article  PubMed  Google Scholar 

  12. Lu DS, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168(6):1439–43.

    Article  CAS  PubMed  Google Scholar 

  13. Tamm EP, et al. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging. 2006;31(5):568–74.

    Article  CAS  PubMed  Google Scholar 

  14. Christians KK, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19(3):266–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kharofa J, et al. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiother Oncol. 2014;113(1):41–6.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Chatzizacharias NA, et al. Locally advanced pancreas cancer: staging and goals of therapy. Surgery. 2018;163:1053.

    Article  PubMed  Google Scholar 

  17. Tsai S, et al. Multimodality therapy in patients with borderline resectable or locally advanced pancreatic cancer: importance of locoregional therapies for a systemic disease. J Oncol Pract. 2016;12(10):915–23.

    Article  PubMed  Google Scholar 

  18. Winter JM, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199–210; discussion 1210–1.

    Article  PubMed  Google Scholar 

  19. Fatima J, et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010;145(2):167–72.

    Article  PubMed  Google Scholar 

  20. Neoptolemos JP, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bilimoria KY, et al. Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg. 2008;207(4):510–9.

    Article  PubMed  Google Scholar 

  22. Katz MH, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Tran Cao HS, et al. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014;18(2):269–78; discussion 278.

    Article  PubMed  Google Scholar 

  24. Leach SD, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg. 1998;85(5):611–7.

    Article  CAS  PubMed  Google Scholar 

  25. Tseng JF, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8):935–49; discussion 949–50.

    Article  PubMed  Google Scholar 

  26. Nagakawa T, et al. Patterns of neural and plexus invasion of human pancreatic cancer and experimental cancer. Int J Pancreatol. 1991;10(2):113–9.

    CAS  PubMed  Google Scholar 

  27. Brugge WR, Van Dam J. Pancreatic and biliary endoscopy. N Engl J Med. 1999;341(24):1808–16.

    Article  CAS  PubMed  Google Scholar 

  28. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105–19.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB. 2015;17(10):942–52. https://doi.org/10.1111/hpb.12448.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Tian F, et al. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg. 1992;215(4):350–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Hernandez JM, et al. CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg. 2009;13(2):349–53.

    Article  PubMed  Google Scholar 

  32. Hata S, et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2012;19(2):636–41.

    Article  PubMed  Google Scholar 

  33. Montgomery RC, et al. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997;4(7):551–6.

    Article  CAS  PubMed  Google Scholar 

  34. Khawaja MR, et al. Adjuvant gemcitabine and gemcitabine-based chemoradiotherapy versus gemcitabine alone after pancreatic cancer resection: the Indiana University experience. Am J Clin Oncol. 2017;40(1):42–6.

    Article  CAS  PubMed  Google Scholar 

  35. Sohn TA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567–79.

    Article  CAS  PubMed  Google Scholar 

  36. Hishinuma S, et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10(4):511–8.

    Article  PubMed  Google Scholar 

  37. Smeenk HG, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246(5):734–40.

    Article  PubMed  Google Scholar 

  38. Klinkenbijl JH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82; discussion 782–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Neoptolemos JP, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10.

    Article  CAS  PubMed  Google Scholar 

  40. Abrams RA, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1751–6.

    Article  PubMed  Google Scholar 

  41. Chun YS, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol. 2010;17(11):2832–8.

    Article  PubMed  Google Scholar 

  42. Takahashi H, et al. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery. 2011;150(3):547–56.

    Article  PubMed  Google Scholar 

  43. Sadot E, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22(11):3512–21.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Gillen S, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Chuong MD, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013;86(3):516–22.

    Article  PubMed  Google Scholar 

  46. Mahadevan A, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;78(3):735–42.

    Article  PubMed  Google Scholar 

  47. Rajagopalan MS, et al. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol. 2013;8:254.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Evans DB, George B, Tsai S. Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy. Ann Surg Oncol. 2015;22(11):3409–13.

    Article  PubMed  Google Scholar 

  50. Lassen K, et al. Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations. World J Surg. 2013;37(2):240–58.

    Article  PubMed  Google Scholar 

  51. Takagi K, et al. Effect of an enhanced recovery after surgery protocol in patients undergoing pancreaticoduodenectomy: a randomized controlled trial. Clin Nutr. 2019;38:174–81.

    Article  PubMed  Google Scholar 

  52. Xiong J, et al. Enhanced recovery after surgery program in patients undergoing pancreaticoduodenectomy: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016;95(18):e3497.

    Article  CAS  Google Scholar 

  53. Katz MH, et al. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008;248(6):1098–102.

    Article  PubMed  Google Scholar 

  54. Pilgrim CH, et al. Mesocaval shunting: a novel technique to facilitate venous resection and reconstruction and enhance exposure of the superior mesenteric and celiac arteries during pancreaticoduodenectomy. J Am Coll Surg. 2013;217(3):e17–20.

    Article  PubMed  Google Scholar 

  55. Christians KK, et al. Arterial resection at the time of pancreatectomy for cancer. Surgery. 2014;155(5):919–26.

    Article  PubMed  Google Scholar 

  56. Fortner JG. Regional resection of cancer of the pancreas: a new surgical approach. Surgery. 1973;73(2):307–20.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA

    Callisia N. Clarke

Authors
  1. Callisia N. Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Callisia N. Clarke .

Editor information

Editors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA

    Susan Tsai

  2. Division of Medical Oncology, Department of Medicine, The Medical College of Wisconsin, Milwaukee, WI, USA

    Paul S. Ritch

  3. Department of Radiation Oncology, The Medical College of Wisconsin, Milwaukee, WI, USA

    Beth A. Erickson

  4. Department of Surgery, The Medical College of Wisconsin, Milwaukee, WI, USA

    Douglas B. Evans

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Clarke, C.N. (2019). Treatment Sequencing for Borderline Resectable Pancreatic Cancer. In: Tsai, S., Ritch, P., Erickson, B., Evans, D. (eds) Management of Localized Pancreatic Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-98944-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98944-0_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98943-3

  • Online ISBN: 978-3-319-98944-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation